All mouse studies were approved by the University of Cincinnati Institutional Animal Care and Use Committee (IACUC) (protocol: 07-01-11-01, approval date: 17 September 2018) that maintains an American Association of Assessment and Accreditation of Laboratory Animal Care (AAALAC) facility. C57BL/6 mice purchased from Jackson Laboratories were orthotopically transplanted with 500,000 7940B cells derived from a primary spontaneous PDAC tumor arising in the body of the pancreas (C57BL/6) of a male transgenic KrasLSL-G12D/+, Trp53LSL-R172H/+, Pdx1-Cre (KPC) mouse [39 (link),40 (link)] (kindly donated by Dr. Gregory Beatty, University of Pennsylvania). Nod scid gamma mice were orthotopically transplanted with 500–1000 pancreatic cancer organoids derived from PDAC patients.
In a separate series of experiments, 7 days post-orthotopic transplantation, C57BL/6 mice (Jackson Laboratories) were treated with gemcitabine (Selleckchem, S1149) (325 μg/mouse, i.p.) every 2 weekdays and Epothilone A (abaraxane, Selleckchem, S1297) (13 μg/mouse, i.v.) every 5 days, InVivoPlus anti-mouse PD-1 (BioXCell, BP0146) (200 μg/mouse, i.p.) every 5 days, Cabozantinib (cabo, Selleckchem, S1119) (780 μg/mouse, oral gavage) every weekday or a combination of 3 or 4 drugs for 7 days. The mice were sacrificed, tumors were removed and weighed.
In a separate series of experiments, 7 days post-orthotopic transplantation, C57BL/6 mice (Jackson Laboratories) were treated with gemcitabine (Selleckchem, S1149) (325 μg/mouse, i.p.) every 2 weekdays and Epothilone A (abaraxane, Selleckchem, S1297) (13 μg/mouse, i.v.) every 5 days, InVivoPlus anti-mouse PD-1 (BioXCell, BP0146) (200 μg/mouse, i.p.) every 5 days, Cabozantinib (cabo, Selleckchem, S1119) (780 μg/mouse, oral gavage) every weekday or a combination of 3 or 4 drugs for 7 days. The mice were sacrificed, tumors were removed and weighed.
Free full text: Click here
